Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MAT2A inhibitor in cancer cell lines

ABSTRACT: MAT2A inhibitor is dosed to MTAP null cell lines, samples are collected for transcriptome profiling

ORGANISM(S): Homo sapiens

PROVIDER: GSE161706 | GEO | 2020/12/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

MAT2A inhibitor in cancer cell lines

Project description:MAT2A inhibitor in cancer cell lines

| PRJNA679231 | ENA

Transcripitional profiling of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment

Project description:RNA-seq analysis of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment. The analysis revealed that inhibition of MAT2A or BET factors suppresses the expression of genes regulating cell cycle progression and additional cellular programs.

2022-02-28 | GSE184065 | GEO

MAT2A and methionine dependency are indispensible for H3K27M mutant gliomas.

Project description:Gliomas bearing driver mutations of histone 3 lysine 27 (H3K27M) are incurable brain tumors. H3K27M mutant tumors display unique epigenomes with global loss of the chromatin repressive H3K27 trimethylation mark. Here, we generated a syngeneic H3K27M mouse model to study the dependence upon amino acid (AA) metabolism by performing an AA drop out screen. H3K27M mutant cells, but not histone wildtype cells, were highly dependent on the amino acid, methionine. Interrogating the methionine cycle dependency through an siRNA screen identified the enzyme Methionine Adenosyltransferase 2A (MAT2A), which catalyzes production of S-adenosylmethionine (SAM), a methyl donor. Sensitivity to MAT2A loss in H3K27M mutant cells was not mediated through the canonical mechanism of MTAP deletion; instead, H3K27M mutant cells have lower MAT2A protein levels, which is mediated by Adenosylmethionine Decarboxylase 1 (AMD1) production of decarboxylated SAM (dcSAM). MAT2A loss induces global depletion of H3K36me3, a potent chromatin mark of transcriptional elongation, as evaluated by quantitative chromatin immunoprecipitation with reference exogenous genome sequencing (ChIP-Rx-Seq) in multiple DIPG lines. Tandem H3K36me3 ChIP-Rx-seq and RNA-seq identified several oncogenic and developmental transcriptional programs associated with MAT2A loss. Moreover, inducible knockdown of MAT2A or methionine-restricted diets (MR) extended survival in both syngeneic and patient-derived xenograft models (PDXs) in vivo. Collectively, our results provide novel connections between AA metabolism and the epigenome in H3K27M gliomas, suggesting that MAT2A, a central regulator of methionine metabolism, presents exploitable therapeutic vulnerabilities in H3K27M gliomas.

2022-01-28 | GSE160006 | GEO

Transcriptomic profile in in vitro produced bovine morulae treated with MAT2A inhibitor

Project description:We obtained transcriptomic profiles in bovine morulae which had been in vitro treated with a methionine adenosyltransferase 2A (MAT2A) inhibitor from the 8-16 cell stage.

2022-05-31 | GSE198294 | GEO

Genome-wide H3K27me3 profile in in vitro produced bovine morula treated with MAT2A inhibitor

Project description:We obtained genome-wide profiles of histone H3 lysine 27 trimethylation (H3K27me3) in bovine morula which had been in vitro treated with a methionine adenosyltransferase 2A (MAT2A) inhibitor from the 8-16 cell stage. Sequencing center: NODAI Genome Research Center, Tokyo University of Agriculture

2022-05-31 | GSE198293 | GEO

MAT2A as key regulator and therapeutic target in MLL leukemogenesis

Project description:Epigenetic dysregulation plays a pivotal role in MLL pathogenesis, therefore serving as suitable therapeutic point of attack. SAM is the universal methyl donor in human cells and is synthesized by MAT2A. MAT2A is already known to be deregulated in different cancer types. Here, we used our human CRISPR/Cas9-MLLr leukemia model, faithfully mimicking MLL patients’ pathology with indefinite growth potential in in vitro culture, to evaluate the unknown role of MAT2A as therapeutic target. Comparable to publicly available patient data, we detected MAT2A to be significantly overexpressed in our CRISPR/Cas9-MLLr model compared to healthy controls. By using non-MLLr and MLLr cell lines and our model, we detected an MLLr specific enhanced response to PF-9366, a new MAT2A inhibitor, by alteration of proliferation, viability, differentiation, apoptosis and cell cycling. Moreover, the combinational treatment of PF-9366 with chemotherapy or targeted therapies against the SAM-dependent methyltransferases DOT1L and PRMT5, revealed even more pronounced effects. In summary, we uncovered MAT2A as a key regulator in MLL leukemogenesis and its inhibition led to significant anti-leukemic effects. Therefore, our study paves the avenue for clinical application of PF-9366 to improve the treatment of poor prognosis MLLr leukemia.

2020-06-22 | GSE141839 | GEO

Profile in in vitro produced bovine morulae treated with MAT2A inhibitor

Project description:Profile in in vitro produced bovine morulae treated with MAT2A inhibitor

| PRJNA814505 | ENA

Transcripitional profiling of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment

Project description:Transcripitional profiling of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment

| PRJNA762980 | ENA

NUDT21 regulates intron detention of the SAM synthetase MAT2A RNA

Project description:NUDT21 encodes the CFIm25 protein, a component of the CFIm complex that regulates alternative polyadenylation (APA). Our data suggest that the CFIm complex also induces splicing of a detained intron in the the S-adenosylmethionine (SAM) synthetase MAT2A to control intracellular levels of SAM. To genetically separate these functions, we used poly(A) Click-seq (PAC-seq) to determine the changes in poly(A) site selection in two cell lines. The parental cell line is the colorectal cell line HCT116 and a derivative line that has the detained intron of MAT2A deleted in both alleles of MAT2A (116-DDI). We found few differences in alternative polyadenylation after CFIm25 depletion were similar supporting teh conclusion that CFIm's role in APA is mechanistically distinct from its role in regulation of MATA splicing.

2021-05-04 | GSE158591 | GEO

Transcriptomic profile in in vitro produced bovine morulae treated with MAT2A inhibitor

Project description:Transcriptomic profile in in vitro produced bovine morulae treated with MAT2A inhibitor

| PRJNA814512 | ENA